iRhythm Holdings, Inc. Common Stock
IRTC
$116.92
-7.53%
iRhythm Holdings, Inc. is a digital healthcare company that designs and commercializes the Zio System, a wearable biosensor and cloud-based analytics platform for ambulatory cardiac monitoring, operating in the medical devices industry. The company is a market leader in long-duration, patch-based ECG monitoring, differentiated by its FDA-cleared, 14-day continuous monitoring capability and proprietary AI-driven data analysis. The current investor narrative centers on the company's accelerating revenue growth, a recent return to quarterly profitability, and its strong position in the expanding cardiac arrhythmia diagnostic market, while also debating the sustainability of its growth and the impact of reimbursement dynamics and competitive pressures.…
IRTC
iRhythm Holdings, Inc. Common Stock
$116.92
Investment Opinion: Should I buy IRTC Today?
Rating: Buy. IRTC is a high-growth medical device company with accelerating revenue and a recent return to profitability, supported by a Strong Buy analyst consensus and an average price target of $176.86, implying 39.9% upside. The thesis is that the Zio System's market leadership and AI-driven analytics will drive sustained double-digit growth, leading to continued margin expansion and earnings growth.
Sign up to view all
IRTC 12-Month Price Forecast
The AI model assesses IRTC as bullish over the next 12 months, driven by strong revenue acceleration and a recent return to profitability. The company's high gross margin and market leadership in cardiac monitoring support continued growth, while the stock's valuation near historical lows offers a favorable risk/reward. However, the high forward P/E and competitive risks warrant a medium confidence level. The stance would be upgraded to high confidence if the company delivers two consecutive quarters of profitability and revenue growth above 25%, while a downgrade to neutral would occur if growth decelerates below 15% or margins compress significantly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on iRhythm Holdings, Inc. Common Stock's 12-month outlook, with a consensus price target around $176.86 and implied upside of +51.3% versus the current price.
Average Target
$176.86
0 analysts
Implied Upside
+51.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$157 - $200
Analyst target range
Analyst consensus is a Strong Buy, with 14 analysts covering the stock and a mean recommendation of 1.13 (where 1 is Strong Buy). The average price target is $176.86, implying 39.9% upside from the current price of $126.44. The low target is $157.00 (24.2% upside) and the high target is $200.00 (58.2% upside), indicating a relatively wide range that reflects uncertainty about the company's growth trajectory and profitability. Recent ratings have been overwhelmingly positive, with firms like Citigroup, Truist, and Baird reiterating Buy or Outperform ratings in early 2026, and no downgrades in the past six months, suggesting strong institutional conviction in the stock's recovery.
Bulls vs Bears: IRTC Investment Factors
IRTC presents a compelling bull case with accelerating revenue growth, a return to profitability, and strong analyst support, but bears highlight elevated valuation, persistent underperformance, and high leverage. The evidence currently leans slightly bullish given the strong growth trajectory and analyst conviction, but the key tension is whether the company can sustain its growth and profitability to justify its premium valuation. If revenue growth continues at 25%+ and margins expand, the stock could re-rate higher; if growth decelerates or reimbursement pressures emerge, the stock could face significant downside.
Bullish
- Accelerating Revenue Growth: Q4 2025 revenue grew 27.1% YoY to $208.9M, up from 16.5% growth in Q4 2024, with sequential acceleration from $158.7M in Q1 2025. This outpaces the broader medical device industry, indicating strong adoption of the Zio System.
- Return to Profitability: The company posted its first profitable quarter in Q4 2025 with EPS of $0.17 and net income of $5.6M, a significant turnaround from losses earlier in the year. This demonstrates improving operating leverage and cost discipline.
- High Gross Margin: Gross margin expanded to 70.9% in Q4 2025, up from 70.0% in Q4 2024, reflecting pricing power and scale benefits. This provides a strong foundation for future profitability as revenue grows.
- Strong Analyst Conviction: Analyst consensus is Strong Buy with a mean recommendation of 1.13 (1=Strong Buy) from 14 analysts. The average price target of $176.86 implies 39.9% upside, with no downgrades in the past six months.
Bearish
- High Valuation Despite Losses: Forward P/E is 105.9, and trailing P/E is negative at -127.7, indicating the market is pricing in substantial future earnings growth. The P/S ratio of 7.6 is 117% above the industry average of 3.5, leaving little room for error.
- Persistent Underperformance: The stock is down 22.0% over the past year and 27.8% YTD, while the S&P 500 gained 20.4% and 13.9% respectively. This relative weakness suggests negative sentiment and potential structural concerns.
- High Debt-to-Equity: Debt-to-equity ratio is 4.79, indicating significant leverage. While the current ratio of 4.63 provides liquidity, the high debt load could strain cash flows if growth slows or interest rates remain elevated.
- Negative Operating Margin: Despite the profitable quarter, the trailing twelve-month operating margin is -4.9%, and net margin is -6.0%. The company's profitability is recent and may not be sustainable if revenue growth decelerates.
IRTC Technical Analysis
IRTC is in a clear downtrend over the past year, with the stock down 22.0% over the last 12 months, significantly underperforming the S&P 500, which gained 20.4% over the same period. The current price of $126.44 sits at 22.4% of its 52-week range (between $100.85 low and $212.00 high), indicating the stock is near its lows, which could represent a value opportunity or reflect ongoing negative sentiment. The stock has also declined 27.8% year-to-date, while the S&P 500 is up 13.9%, highlighting persistent relative weakness.
Beta
1.32
1.32x market volatility
Max Drawdown
-46.2%
Largest decline past year
52-Week Range
$101-$212
Price range past year
Annual Return
-27.2%
Cumulative gain past year
| Period | IRTC Return | S&P 500 |
|---|---|---|
| 1m | +5.4% | +4.0% |
| 3m | +2.7% | +5.3% |
| 6m | -24.0% | +12.6% |
| 1y | -27.2% | +20.1% |
| ytd | -33.3% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IRTC Fundamental Analysis
Revenue growth is accelerating, with Q4 2025 revenue of $208.9 million representing a 27.1% year-over-year increase, up from 16.5% growth in Q4 2024. The company's revenue trajectory has been consistently strong, with sequential growth from $158.7 million in Q1 2025 to $208.9 million in Q4 2025, driven by robust demand across commercial payors ($111.7 million), Medicare & Medicaid ($49.2 million), and healthcare institutions ($34.3 million). This growth is outpacing the broader medical device industry, suggesting strong market adoption of the Zio System.
Quarterly Revenue
$208890000.0B
2025-12
Revenue YoY Growth
+27.1%
YoY Comparison
Gross Margin
70.9%
Latest Quarter
Free Cash Flow
$34521000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IRTC Overvalued?
Given the company's recent profitability, the trailing P/E ratio is negative at -127.7, but the forward P/E is 105.9, indicating the market expects continued earnings growth. The P/S ratio of 7.6 is elevated compared to the industry average of 3.5, representing a 117% premium, which may be justified by the company's superior growth and gross margin of 70.6%. Historically, the stock's P/S ratio has ranged from 15.6 to 50.5 over the past three years, and the current 7.6 is near the bottom of that range, suggesting the stock is trading at a significant discount to its own historical valuation.
PE
-127.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-1557.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: IRTC carries a high debt-to-equity ratio of 4.79, which amplifies financial risk, though the current ratio of 4.63 indicates strong short-term liquidity. The company's recent profitability is fragile, with a trailing net margin of -6.0% and operating margin of -4.9%, meaning any revenue shortfall could quickly return it to losses. Revenue concentration is a concern, as a significant portion comes from commercial payors ($111.7M in Q4 2025) and Medicare/Medicaid ($49.2M), making the business sensitive to reimbursement policy changes. Additionally, the company's high valuation (P/S 7.6) leaves little room for earnings disappointments, as any miss could trigger sharp multiple compression.